sellWeak cluster of 3
Christopher Yea sold $31k of KALV
CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc.. 2,600 shares at an average of $11.84, traded May 19, 2025, filed May 20, 2025.
Warning score
20Value
$31k
2,600 shares
Holdings after
95,557
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +5Trade size$31k at market
- 0Share of holdings soldSold 2.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-013870, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 17, 2025 | MOption exercise Common Stock | +4,205 | - | - | 98,157 | May 20, 2025 |
| May 19, 2025 | SOpen-market sale Common Stock | -2,600 | $11.84 | $31k | 95,557 | May 20, 2025 |
| May 17, 2025 | MOption exercise Restricted Stock Unitderivative | -1,774 | $0.00 | $0 | 7,095 | May 20, 2025 |
| May 17, 2025 | MOption exercise Restricted Stock Unitderivative | -2,431 | $0.00 | $0 | 4,861 | May 20, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $71k 5,296 shares | -4% | |
| 6Weak | KALVsell KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $45k 3,075 shares | -2% | |
| 35Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $116k 7,294 shares | -2% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $31k 2,336 shares | -2% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $26k 1,954 shares | -1% | |
| 15Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $20k 1,480 shares | -4% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $39k 2,942 shares | -2% | |
| 36Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $145k 10,940 shares | -3% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $31k 2,362 shares | -2% | |
| 15Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $25k 1,864 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.